Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright’s AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the COVID-19 Delta B.1.617.2 variant
  • Therma Bright’s AcuVid™ saliva test has successfully detected the P.1 and P.2 variants, the B.1.1.7 variant and the highly-contagious Delta B.1.617.2 variant
  • Therma Bright is a progressive medical diagnostic and device technology company
  • Therma Bright Inc. (THRM) opened trading at C$0.305 per share

Therma Bright (THRM) has confirmed that its AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the COVID-19 Delta B.1.617.2 variant.

The AcuVid™ / Delta variant study was completed at the company’s Brazilian clinical study partner’s lab location at the Federal University of Minas Gerais.

Ever since the SARS-CoV-2 Coronavirus became a global pandemic in 2020, new variants have emerged, and the scientific community has worked to evaluate each strain and its impact on our health.

The Delta B.1.617.2 variant has now become the dominant COVID-19 strain around the world. The World Health Organization has urged fully vaccinated people to continue wearing masks due to this new variant strain.

On June 24th Therma Bright and its partners initiated the Delta variant study. The study focused on ensuring Therma Bright’s AcuVid™ COVID-19 Rapid Antigen Saliva Test would detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus. To date, Therma Bright’s AcuVid™ Rapid Antigen Saliva Test has successfully detected not only the original virus but the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant from the UK and now the highly-contagious Delta B.1.617.2 variant from India.

“We believe that the spread of the COVID-19 virus can be mitigated by early detection through serial testing of individuals,” expressed Rob Fia, CEO of Therma Bright.

“Many antigen test manufacturers believe their solutions will be able to detect these new, mutating variants. At Therma Bright, we have gone that extra mile to conduct the critical research to validate and ensure our AcuVid™ COVID-19 Rapid Antigen Saliva Test does indeed successfully detect not only the original COVID-19 virus, but all major variants, including this fast moving and most contagious Delta strain.”

Therma Bright is a progressive medical diagnostic and device technology company focused on providing innovative solutions that address some of today’s most important medical and healthcare challenges.

Therma Bright Inc. (THRM) opened trading at C$0.305 per share.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.
Red Light Holland - Partner, Wiz Khalifa.

" Red Light Holland (CSE:TRIP) partners with Wiz Khalifa

Red Light Holland (TRIP) and rapper Wiz Khalifa will launch Mistercap, a new psilocybin brand.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.